A randomized clinical trial comparing prompt photodynamic therapy with 3 months observation in patients with acute central serous chorioretinopathy with central macular leakage.
Tom Oar MissottenJohan G HoddenbachChristine Ae EenhorstL Ingeborgh van den BornJosé P Martinez CirianoRene J WubbelsPublished in: European journal of ophthalmology (2020)
The (intended) number of photodynamic therapy (re)treatments in group II (n = 15) was 46% less than in group I (n = 28). Visual acuity and central foveal thickness at 12 months were similar. Therefore, the preferred management of acute central serous chorioretinopathy at presentation appears to be observation for 3 months.